A phase 2 study of first-line (1L) domvanalimab (dom), zimberelimab (zim), and chemotherapy (chemo) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Substudy-01 of the VELOCITY-HNSCC platform trial.

Authors: Riddhi Patel, Kevin Joseph Harrington, Myung-Ju Ahn, Lisa F. Licitra, Douglas Adkins, Amaury Daste, Irene Brana, Muh-Hwa Yang, Jin You, Kun Xu, Manish Monga, Ye Guo

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e18011

Source: Full article

---

Abstract

e18011